Shidong Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shidong Zhao has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Dongkui Xu
Department of VIP , National Cancer Center & National Clinical Research Center for Cancer & Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , China
4 shared publications - Donglai Wang
State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
4 shared publications - Han Yao
State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
4 shared publications - Jingyuan Ning
State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
4 shared publications - Meng Zhang
State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
4 shared publications - Wei Gu
Institute for Cancer Genetics, and Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, USA
4 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-18 from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Supplementary Figure 1 Host p53 regulates cancer immunotherapy in melanoma model. Supplementary Figure 2 Analysis of tumor-infiltrating cells in response to PI immunotherapy. Supplementary Figure 3 Cd8+ T cells are essential for tumor suppression in response to PI immunotherapy. Supplementary Figure 4 Establishment of PDX-based immunotherapeutic model with humanized mouse. Supplementary Figure 5 Further analysis of T cell-intrinsic p53 CTD acetylation in response to immunotherapy. Supplementary Figure 6 Generation of the p53fl7KR/fl7KR cKI mouse model. Supplementary Figure 7 CTD acetylation of T cell-intrinsic p53 contributes to PI immunotherapy in melanoma model. Supplementary Figure 8 Generation and characterization of p53fl7KQ/fl7KQ cKI mouse model. Supplementary Figure 9 Functional analysis of tumor-infiltrating T cells in p53+/-, Lck-Cre and p53fl7KQ/-, Lck-Cre mice. Supplementary Figure 10 CTD acetylation-mimicking p53 in T cells regulates antitumor immunity in melanoma model. Supplementary Figure 11 The effect of PI immunotherapy in p53fl7KQ/-, Lck-Cre recipient mice. Supplementary Figure 12 Activation of T cell-intrinsic p53 slightly enhances T cell-mediated cytotoxicity. Supplementary Figure 13 scRNA-seq analysis of tumor-infiltrating lymphocytes. Supplementary Figure 14 Functional analysis of Ccl5 in T cell-intrinsic p53-mediated antitumor immunity. Supplementary Figure 15 Activation of the IFN-γ pathway promotes Ccl5 transcriptional expression in Cd8+ T cells. Supplementary Figure 16 Further analysis of the crosstalk between p53 CTD acetylation and IFN-γ. Supplementary Figure 17 Mechanistic details of VPRBP-mediated repression of p53-dependent Ifng transcription. Supplementary Figure 18 Further analysis of IFN-γ/JAK-STAT pathways regulated by p53 CTD acetylation in Cd8+ T cells.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-18 from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Supplementary Figure 1 Host p53 regulates cancer immunotherapy in melanoma model. Supplementary Figure 2 Analysis of tumor-infiltrating cells in response to PI immunotherapy. Supplementary Figure 3 Cd8+ T cells are essential for tumor suppression in response to PI immunotherapy. Supplementary Figure 4 Establishment of PDX-based immunotherapeutic model with humanized mouse. Supplementary Figure 5 Further analysis of T cell-intrinsic p53 CTD acetylation in response to immunotherapy. Supplementary Figure 6 Generation of the p53fl7KR/fl7KR cKI mouse model. Supplementary Figure 7 CTD acetylation of T cell-intrinsic p53 contributes to PI immunotherapy in melanoma model. Supplementary Figure 8 Generation and characterization of p53fl7KQ/fl7KQ cKI mouse model. Supplementary Figure 9 Functional analysis of tumor-infiltrating T cells in p53+/-, Lck-Cre and p53fl7KQ/-, Lck-Cre mice. Supplementary Figure 10 CTD acetylation-mimicking p53 in T cells regulates antitumor immunity in melanoma model. Supplementary Figure 11 The effect of PI immunotherapy in p53fl7KQ/-, Lck-Cre recipient mice. Supplementary Figure 12 Activation of T cell-intrinsic p53 slightly enhances T cell-mediated cytotoxicity. Supplementary Figure 13 scRNA-seq analysis of tumor-infiltrating lymphocytes. Supplementary Figure 14 Functional analysis of Ccl5 in T cell-intrinsic p53-mediated antitumor immunity. Supplementary Figure 15 Activation of the IFN-γ pathway promotes Ccl5 transcriptional expression in Cd8+ T cells. Supplementary Figure 16 Further analysis of the crosstalk between p53 CTD acetylation and IFN-γ. Supplementary Figure 17 Mechanistic details of VPRBP-mediated repression of p53-dependent Ifng transcription. Supplementary Figure 18 Further analysis of IFN-γ/JAK-STAT pathways regulated by p53 CTD acetylation in Cd8+ T cells.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Although p53 plays a central role in tumor suppression, how it is regulated in T cells to exert antitumor effects remains unclear. In this study, we show that activation of T cell–intrinsic p53 via carboxyl-terminal domain (CTD) acetylation during immunotherapy activates the IFN-γ pathway, promotes CD8+ T-cell infiltration, and elicits CD8+ T cell–dependent antitumor immunity. Using T cell–specific knockin mouse models, we demonstrate that loss of CTD acetylation in T cells abrogates CD8+ T cell–dependent antitumor immunity whereas expression of CTD acetylation–mimicking p53 in T cells enhances this immune response. Moreover, we identify IFNG as a direct target of T cell–intrinsic p53 and uncover a positive feedback loop between p53 and the IFN-γ pathway for enhancing T cell–dependent antitumor immunity. Our study reveals that CTD acetylation–mediated activation of T cell–intrinsic p53 promotes antitumor immunity in response to immunotherapy, highlighting a non–tumor cell–autonomous mechanism of p53 action by regulating adoptive immune responses.Significance:This study identifies T cell–intrinsic p53 as a key determinant of immunotherapy efficacy. CTD acetylation, rather than stabilization, activates a p53–IFN-γ feedback loop and promotes CD8+ T cell–mediated antitumor immunity independently of tumor p53 status. These findings reveal a non–tumor cell–autonomous action of p53 to boost PD-1–based immunotherapy.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Although p53 plays a central role in tumor suppression, how it is regulated in T cells to exert antitumor effects remains unclear. In this study, we show that activation of T cell–intrinsic p53 via carboxyl-terminal domain (CTD) acetylation during immunotherapy activates the IFN-γ pathway, promotes CD8+ T-cell infiltration, and elicits CD8+ T cell–dependent antitumor immunity. Using T cell–specific knockin mouse models, we demonstrate that loss of CTD acetylation in T cells abrogates CD8+ T cell–dependent antitumor immunity whereas expression of CTD acetylation–mimicking p53 in T cells enhances this immune response. Moreover, we identify IFNG as a direct target of T cell–intrinsic p53 and uncover a positive feedback loop between p53 and the IFN-γ pathway for enhancing T cell–dependent antitumor immunity. Our study reveals that CTD acetylation–mediated activation of T cell–intrinsic p53 promotes antitumor immunity in response to immunotherapy, highlighting a non–tumor cell–autonomous mechanism of p53 action by regulating adoptive immune responses.Significance:This study identifies T cell–intrinsic p53 as a key determinant of immunotherapy efficacy. CTD acetylation, rather than stabilization, activates a p53–IFN-γ feedback loop and promotes CD8+ T cell–mediated antitumor immunity independently of tumor p53 status. These findings reveal a non–tumor cell–autonomous action of p53 to boost PD-1–based immunotherapy.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Source Data 1 from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
This file contains the raw data of this study.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSource Data 1 from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
This file contains the raw data of this study.
- 19 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (1) , 155-176
Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Although p53 plays a central role in tumor suppression, how it is regulated in T cells to exert antitumor effects remains unclear. In this study, we show that activation of T cell–intrinsic p53 via carboxyl-terminal domain (CTD) acetylation during immunotherapy activates the IFN-γ pathway, promotes CD8+ T-cell infiltration, and elicits CD8+ T cell–dependent antitumor immunity. Using T cell–specific knockin mouse models, we demonstrate that loss of CTD acetylation in T cells abrogates CD8+ T cell–dependent antitumor immunity whereas expression of CTD acetylation–mimicking p53 in T cells enhances this immune response. Moreover, we identify IFNG as a direct target of T cell–intrinsic p53 and uncover a positive feedback loop between p53 and the IFN-γ pathway for enhancing T cell–dependent antitumor immunity. Our study reveals that CTD acetylation–mediated activation of T cell–intrinsic p53 promotes antitumor immunity in response to immunotherapy, highlighting a non–tumor cell–autonomous mechanism of p53 action by regulating adoptive immune responses. Significance: This study identifies T cell–intrinsic p53 as a key determinant of immunotherapy efficacy. CTD acetylation, rather than stabilization, activates a p53–IFN-γ feedback loop and promotes CD8+ T cell–mediated antitumor immunity independently of tumor p53 status. These findings reveal a non–tumor cell–autonomous action of p53 to boost PD-1–based immunotherapy.
- 19 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (1) , 155-176
Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Although p53 plays a central role in tumor suppression, how it is regulated in T cells to exert antitumor effects remains unclear. In this study, we show that activation of T cell–intrinsic p53 via carboxyl-terminal domain (CTD) acetylation during immunotherapy activates the IFN-γ pathway, promotes CD8+ T-cell infiltration, and elicits CD8+ T cell–dependent antitumor immunity. Using T cell–specific knockin mouse models, we demonstrate that loss of CTD acetylation in T cells abrogates CD8+ T cell–dependent antitumor immunity whereas expression of CTD acetylation–mimicking p53 in T cells enhances this immune response. Moreover, we identify IFNG as a direct target of T cell–intrinsic p53 and uncover a positive feedback loop between p53 and the IFN-γ pathway for enhancing T cell–dependent antitumor immunity. Our study reveals that CTD acetylation–mediated activation of T cell–intrinsic p53 promotes antitumor immunity in response to immunotherapy, highlighting a non–tumor cell–autonomous mechanism of p53 action by regulating adoptive immune responses. Significance: This study identifies T cell–intrinsic p53 as a key determinant of immunotherapy efficacy. CTD acetylation, rather than stabilization, activates a p53–IFN-γ feedback loop and promotes CD8+ T cell–mediated antitumor immunity independently of tumor p53 status. These findings reveal a non–tumor cell–autonomous action of p53 to boost PD-1–based immunotherapy.
- Open Access
- 27 June 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (26) , e42791
Gut microbiota causally affects ulcerative colitis by potential mediation of plasma metabolites: A Mendelian randomization study
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a multifactorial etiology, including genetic, immunological, and environmental factors, as well as alterations in the gut microbiome and plasma metabolites. The interplay between these factors is complex and not fully elucidated, particularly regarding the potential mediation of metabolites in the relationship between gut microbiota and UC. We performed a Mendelian randomization (MR) study to investigate the causal associations between gut microbiota, plasma metabolites, and UC. The study utilized a two-sample MR approach to discern causal relationships among these factors. Genetic variants from genome-wide association studies served as instrumental variables in the MR analyses, conducted using the “TwoSampleMR” package in R software. We adhered to the fundamental assumptions of MR analyses, ensuring the validity of our causal inferences. Additionally, we incorporated a mediation analysis to assess the potential mediating role of plasma metabolites in the relationship between gut microbiota and UC. Our current study found the substantial relationship between certain gut microbial taxa and the development of UC. Indeed, we have identified 6 microbial taxa, including Genus Dorea, Phylum Proteobacteria, Species Streptococcus parasanguinis, Species Ruminococcus obeum, Species Roseburia intestinalis, and Order Lactobacillales, which were found to be causally related to UC. Seventy-three metabolites and metabolite ratios of were also causally associated with UC, and a mediation analysis revealed that metabolites such as stearoylcarnitine, 3-hydroxyoctanoylcarnitine, 1-arachidonoyl-GPE (20:4n6), 3-(3-hydroxyphenyl)propionate sulfate, and thioproline mediated the effects of gut microbiota on UC and hence might play roles in disease pathogenesis. This microbiota–UC-specific MR study provides evidence for causal associations between specific gut microbiota and UC, potentially mediated through plasma metabolites. The findings give new perspectives on the causal nexus of the gut microbiota and plasma metabolites with UC, highlighting potential intervention targets for the disease. These findings call for confirmation in further research, together with investigation of the underlying mechanisms.
- 27 June 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (26) , e42791
Open AccessGut microbiota causally affects ulcerative colitis by potential mediation of plasma metabolites: A Mendelian randomization study
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a multifactorial etiology, including genetic, immunological, and environmental factors, as well as alterations in the gut microbiome and plasma metabolites. The interplay between these factors is complex and not fully elucidated, particularly regarding the potential mediation of metabolites in the relationship between gut microbiota and UC. We performed a Mendelian randomization (MR) study to investigate the causal associations between gut microbiota, plasma metabolites, and UC. The study utilized a two-sample MR approach to discern causal relationships among these factors. Genetic variants from genome-wide association studies served as instrumental variables in the MR analyses, conducted using the “TwoSampleMR” package in R software. We adhered to the fundamental assumptions of MR analyses, ensuring the validity of our causal inferences. Additionally, we incorporated a mediation analysis to assess the potential mediating role of plasma metabolites in the relationship between gut microbiota and UC. Our current study found the substantial relationship between certain gut microbial taxa and the development of UC. Indeed, we have identified 6 microbial taxa, including Genus Dorea, Phylum Proteobacteria, Species Streptococcus parasanguinis, Species Ruminococcus obeum, Species Roseburia intestinalis, and Order Lactobacillales, which were found to be causally related to UC. Seventy-three metabolites and metabolite ratios of were also causally associated with UC, and a mediation analysis revealed that metabolites such as stearoylcarnitine, 3-hydroxyoctanoylcarnitine, 1-arachidonoyl-GPE (20:4n6), 3-(3-hydroxyphenyl)propionate sulfate, and thioproline mediated the effects of gut microbiota on UC and hence might play roles in disease pathogenesis. This microbiota–UC-specific MR study provides evidence for causal associations between specific gut microbiota and UC, potentially mediated through plasma metabolites. The findings give new perspectives on the causal nexus of the gut microbiota and plasma metabolites with UC, highlighting potential intervention targets for the disease. These findings call for confirmation in further research, together with investigation of the underlying mechanisms.